ICUI vs SUPN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.
SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.
Compare Another Pair
Related Comparisons
ICUI vs SUPN: Head-to-Head Comparison
This page compares ICU Medical, Inc. (ICUI) and Supernus Pharmaceuticals, Inc. (SUPN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.